anaveon
  • About
    • Our Journey
    • About Us
    • Anaveon In Depth
  • Science
    • Our Approach
    • Publications
  • Team
    • Our Team
    • Our Board
    • Our Investors
  • News
  • Career
  • Contact Us
Select Page
HomeJuly
Anaveon to present new data from the Phase I/II study of ANV419 at the ESMO Congress 2022

Anaveon to present new data from the Phase I/II study of ANV419 at the ESMO Congress 2022

by admin | Jul 29, 2022 | Press Releases

Basel, 29 July 2022 – Anaveon today announced that it will present new clinical data from the ongoing Phase I/II study of ANV419 in patients with solid tumors, as well as new pre-clinical data further elucidating the mode of action of this powerful and selective...
Anaveon appoints Dr Gary Phillips as Chief Business Officer

Anaveon appoints Dr Gary Phillips as Chief Business Officer

by admin | Jul 13, 2022 | Press Releases

Dr Phillips brings 30 years of healthcare leadership experience in commercial operations, business strategy, business development and drug development functions.
Anaveon Announces FDA Safe to proceed letter for Investigational New Drug (IND) Application for its no-alpha IL-2 agonist, ANV419

Anaveon Announces FDA Safe to proceed letter for Investigational New Drug (IND) Application for its no-alpha IL-2 agonist, ANV419

by admin | Jul 13, 2022 | Press Releases

Anaveon, a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND application for ANV419-101, a Phase I/II mono treatment dose confirmation and combination dose-finding, global study, in patients with advanced cutaneous melanoma.

Search here

Categories

  • Press Releases 19
  • Uncategorized 1

Recent Posts

  • Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual Meeting
    March 23, 2023
  • Anaveon announces first patient dosed with ANV419 in a Phase I/II Study of ANV419 in patients with multiple myeloma
    March 16, 2023
  • Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma
    February 2, 2023

We are social

Popular Tags

#ANV419 #ESMO22 #phaseI/II 2020 AACR Annual Meeting anaveon brand clinical data CTA approval First patient investment news phase I phase I/II study phase II presentation press solid tumors start trial study data team website

Archives

  • March 2023  2
  • February 2023  1
  • November 2022  2
  • October 2022  1
  • September 2022  1
  • July 2022  3
  • April 2022  1
  • March 2022  1
  • December 2021  1
  • November 2021  1
  • June 2021  1
  • March 2021  1
  • November 2020  1
  • May 2020  1
  • April 2019  1
  • February 2019  1
Anaveon_ submark

Contact us

Email

contact@anaveon.com

Postal Address

Anaveon AG

Technologiepark Basel

Hochbergerstrasse 60C

4057 Basel

Switzerland

Follow us

  • Linkedin
  • Home
  • Privacy Policy
  • Photography Credit

© 2020 All Rights Reserved